Phase 1 Trial Approved to Test PRGN-3005 UltraCAR-T for Advanced Platinum-resistant Ovarian Cancer

Phase 1 Trial Approved to Test PRGN-3005 UltraCAR-T for Advanced Platinum-resistant Ovarian Cancer
Precigen is preparing to launch a Phase 1 trial to test its investigational therapy PRGN-3005 UltraCAR-T for advanced, platinum-resistant ovarian cancer, after the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application. The open-label, dose-escalation study will assess the treatment's safety and maximum tolerated dose. The treatment candidate uses chimeric antigen receptor (CAR) T-cells that are autologous, which means that they originate from the patient’s own immune system. It contains the clinically-validated “Sleeping Beauty” system, which, according to Precigen, enables high-level and stable gene transfer, and contains the cell membrane-bound form of interleukin‐15. This molecule has been shown to promote survival of immune Natural Killer (or NK) cells that have superior anti-tumor properties. "This patient population has limited treatment options and ovarian cancer remains one of the most challenging with minimal advances in long-term survival for patients with advanced disease," Mary L. (Nora) Disis, MD, the trial’s lead investigator and a professor of medicine at the University of Washington, said in a press release. "Clinical advancements and new
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *